Bruker EV/EBIT BRKR

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: 23.1×
10-year median: 24.5×
Against its 10-year history: 34th; percentile: 0 is its lowest day, 100 its highest
10-year range: 16.4× to 44.5×
Peer median: 30.3×

Bruker's EV/EBIT is 23.1× as of Oct 23, 2026.

That is below its ten-year median of 24.5×, lower than on 66% of days in the last ten years.

Over that time it ranged from 16.4× in Dec 2018 to 44.5× in Jul 2026.

The median for 10 diagnostics and research stocks of a similar size is 30.3×.

EV/EBIT over time

median 24.5×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	23.1×	21.7×	44.5×
2025	32.5×	22.2×	34.1×
2024	33.0×	20.7×	33.2×
2023	21.8×	17.5×	28.2×
2022	23.7×	18.2×	28.0×
2021	31.7×	29.7×	41.7×
2020	32.6×	17.5×	33.4×
2019	27.8×	18.0×	30.1×
2018	18.0×	16.4×	27.5×
2017	26.2×	18.4×	27.0×
2016	19.1×	19.1×	30.7×
2015	28.1×	18.0×	28.2×
2014	19.2×	16.6×	22.9×
2013	20.6×	15.5×	21.0×
2012	15.0×	12.2×	17.2×

Against its peers

Companies in Medical - Diagnostics & Research nearest Bruker's size, closest first, today.

Company	EV/EBIT
BRKRBruker	23.1×
CAICaris Life Sciences	56.4×
BIOBio-Rad Laboratories	40.2×
LNTHLantheus	20.6×
BLLNBillionToOne	107×
RVTYRevvity	46.0×
MEDPMedpace	31.4×
VCYTVeracyte	27.2×
CDNACareDx	29.3×
LHLabcorp	21.6×
DGXQuest Diagnostics	19.5×
Peer median	30.3×

Where Bruker ranks

#6of 25Diagnostics and research stocks with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Bruker

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.